Gene: LRRK2

120892
AURA17|DARDARIN|PARK8|RIPK7|ROCO2
leucine rich repeat kinase 2
protein-coding
12q12
Ensembl:ENSG00000188906 MIM:609007 Vega:OTTHUMG00000059742 UniprotKB:Q5S007
NG_011709.1
PubMed
0   ANCO-SNPs
ND|AD
9   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.489e-1 (AD)  5.549e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ZDHHC210.834
MAN1A20.832
ATRX0.831
ZNF7110.827
DMXL10.827
RNF380.826
COG60.825
SNRK0.823
TAB30.823
PPIP5K20.823

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.499
OR4F29-0.448
WDR38-0.335
C7orf61-0.334
HSPA6-0.324
SERPINH1-0.322
S100A1-0.318
LBP-0.314
SRMS-0.308
EVC2-0.307

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5495413-(4-dimethylaminobenzylidene)-1,3-dihydroindol-2-one"3-(4-dimethylaminobenzylidene)-1,3-dihydroindol-2-one results in decreased phosphorylation of LRRK2 protein"23062100
C0259463-methyladenine3-methyladenine inhibits the reaction [LRRK2 gene mutant form results in increased susceptibility to 1-Methyl-4-phenylpyridinium]25017139
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRK2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRK2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of LRRK2 mRNA29067470
D000255Adenosine TriphosphateAdenosine Triphosphate affects the reaction [Magnesium results in increased activity of LRRK2 protein mutant form]20205471
D000255Adenosine TriphosphateAdenosine Triphosphate affects the reaction [Manganese results in increased activity of LRRK2 protein mutant form]20205471
D000255Adenosine TriphosphateLRRK2 protein mutant form results in increased metabolism of Adenosine Triphosphate20205471
D000255Adenosine TriphosphateManganese inhibits the reaction [LRRK2 protein results in increased metabolism of Adenosine Triphosphate]20205471
D000255Adenosine TriphosphateManganese promotes the reaction [LRRK2 protein binds to Adenosine Triphosphate]20205471
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of LRRK2 gene27153756
D000395Air Pollutants, Occupational"Air Pollutants, Occupational results in decreased expression of LRRK2 mRNA"23195993
C002630alpha,beta-methyleneadenosine 5'-triphosphate"Manganese affects the reaction [alpha,beta-methyleneadenosine 5'-triphosphate binds to LRRK2 protein]"20205471
C547126AZM551248AZM551248 results in decreased expression of LRRK2 mRNA22323515
C040929bafilomycin A1LRRK2 gene mutant form results in increased susceptibility to bafilomycin A125017139
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of LRRK2 mRNA21839799
C006780bisphenol Abisphenol A results in increased methylation of LRRK2 gene28505145
C018475butyraldehydebutyraldehyde results in decreased expression of LRRK2 mRNA26079696
D002104CadmiumCadmium results in decreased expression of LRRK2 mRNA21120746
D019327Copper SulfateCopper Sulfate affects the expression of LRRK2 mRNA19549813
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of LRRK2 mRNA]27941970
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of LRRK2 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of LRRK2 mRNA27392435
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of LRRK2 mRNA26924002
D004298DopamineLRRK2 mutant form results in increased susceptibility to [Dopamine co-treated with SLC6A3 protein]23628791
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of LRRK2 mRNA23649840
C540355fenamidonefenamidone results in increased expression of LRRK2 mRNA27029645
C039281furanfuran results in increased expression of LRRK2 mRNA27387713
D017313FenretinideFenretinide results in increased expression of LRRK2 mRNA28973697
D006861Hydrogen PeroxideLRRK2 protein results in increased susceptibility to Hydrogen Peroxide19692353
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LRRK2 mRNA25613284
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of LRRK2 mRNA27392435
C544151jinfukangjinfukang results in decreased expression of LRRK2 mRNA27392435
C035420levodopa methyl ester"[levodopa methyl ester co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LRRK2 mRNA"17614947
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 affects the expression of LRRK2 mRNA"24972896
D008274MagnesiumAdenosine Triphosphate affects the reaction [Magnesium results in increased activity of LRRK2 protein mutant form]20205471
D008274MagnesiumMagnesium promotes the reaction [LRRK2 protein results in increased phosphorylation of LRRK2 protein]20205471
D008274MagnesiumMagnesium promotes the reaction [LRRK2 protein results in increased phosphorylation of MBP protein]20205471
D008274MagnesiumMagnesium results in increased activity of LRRK2 protein mutant form20205471
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA23017109
D008344Maneb[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA23017109
D008344ManebLRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]23017109
D008345ManganeseLRRK2 mutant form results in increased susceptibility to Manganese23628791
D008345ManganeseLRRK2 mutant form results in increased susceptibility to [Manganese co-treated with SLC6A3 protein]23628791
D008345ManganeseAdenosine Triphosphate affects the reaction [Manganese results in increased activity of LRRK2 protein mutant form]20205471
D008345Manganese"Manganese affects the reaction [alpha,beta-methyleneadenosine 5'-triphosphate binds to LRRK2 protein]"20205471
D008345ManganeseManganese inhibits the reaction [LRRK2 protein results in increased metabolism of Adenosine Triphosphate]20205471
D008345ManganeseManganese promotes the reaction [LRRK2 protein binds to Adenosine Triphosphate]20205471
D008345ManganeseManganese promotes the reaction [LRRK2 protein mutant form results in increased phosphorylation of MBP protein]20205471
D008345ManganeseManganese results in decreased activity of LRRK2 protein20205471
D008345ManganeseManganese results in increased activity of LRRK2 protein mutant form20205471
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium promotes the reaction [LRRK2 gene mutant form results in increased activity of CASP3 protein]25017139
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium promotes the reaction [LRRK2 gene mutant form results in increased expression of BECN1 protein]25017139
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium promotes the reaction [LRRK2 gene mutant form results in increased expression of CTSB protein]25017139
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium promotes the reaction [LRRK2 gene mutant form results in increased expression of LAMP2 protein]25017139
D0156551-Methyl-4-phenylpyridinium3-methyladenine inhibits the reaction [LRRK2 gene mutant form results in increased susceptibility to 1-Methyl-4-phenylpyridinium]25017139
D0156551-Methyl-4-phenylpyridiniumCDK5 protein affects the reaction [LRRK2 protein mutant form results in increased susceptibility to 1-Methyl-4-phenylpyridinium]26930193
D0156551-Methyl-4-phenylpyridiniumLRRK2 gene mutant form results in increased susceptibility to 1-Methyl-4-phenylpyridinium25017139
D0156551-Methyl-4-phenylpyridiniumLRRK2 protein mutant form results in increased susceptibility to 1-Methyl-4-phenylpyridinium26930193
D0156321-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"[levodopa methyl ester co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LRRK2 mRNA"17614947
C517284monomethyl phthalatemonomethyl phthalate affects the expression of LRRK2 mRNA26924002
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of LRRK2 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of LRRK2 mRNA"25554681
D009532NickelNickel results in decreased expression of LRRK2 mRNA23195993
D010100OxygenOxygen deficiency results in increased expression of LRRK2 mRNA26516004
D010269ParaquatLRRK2 protein results in decreased susceptibility to Paraquat19625511
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA23017109
D010269Paraquat[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA23017109
D010269ParaquatLRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]23017109
C046012pentanalpentanal results in decreased expression of LRRK2 mRNA26079696
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in decreased expression of LRRK2 mRNA27153767
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of LRRK2 mRNA19710929
C006253pirinixic acidpirinixic acid results in increased expression of LRRK2 mRNA20813756
D010936Plant ExtractsPlant Extracts results in increased expression of LRRK2 mRNA23557933
D011441PropylthiouracilPropylthiouracil results in decreased expression of LRRK2 mRNA24780913
C513428pyrachlostrobinpyrachlostrobin results in increased expression of LRRK2 mRNA27029645
C502851quinocetonequinocetone results in increased expression of LRRK2 mRNA27046791
D012402RotenoneLRRK2 protein results in decreased susceptibility to Rotenone18322385
D012402RotenoneLRRK2 gene polymorphism results in increased susceptibility to Rotenone19741132
D012402RotenoneLRRK2 protein results in decreased susceptibility to Rotenone19625511|2006757
D012402RotenoneLRRK2 protein results in increased susceptibility to Rotenone19692353
D012402RotenonePMK-1 protein affects the reaction [LRRK2 protein results in decreased susceptibility to Rotenone]20067578
D012402RotenonePRKN protein inhibits the reaction [LRRK2 gene polymorphism results in increased susceptibility to Rotenone]19741132
D012402RotenoneSEK-1 protein affects the reaction [LRRK2 protein results in decreased susceptibility to Rotenone]20067578
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of LRRK2 mRNA22298810
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LRRK2 mRNA25613284
C012589trichostatin Atrichostatin A results in increased expression of LRRK2 mRNA24935251
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of LRRK2 mRNA19042947
C013320tris(2-butoxyethyl) phosphatetris(2-butoxyethyl) phosphate affects the expression of LRRK2 mRNA29024780
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRK2 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased methylation of LRRK2 gene29154799
D014635Valproic AcidValproic Acid results in increased expression of LRRK2 mRNA26272509
C029297vinylidene chloridevinylidene chloride results in decreased expression of LRRK2 mRNA26682919
C088658zoledronic acidzoledronic acid results in decreased expression of LRRK2 mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000149SNARE binding-IPI21307259  
GO:0003779actin binding-IPI21307259  
GO:0003924GTPase activity-IDA21048939  
GO:0004672protein kinase activity-IDA16269541  16321986  17442267  21850687  25500533  
GO:0004674protein serine/threonine kinase activity-IDA17200152  19576176  21048939  21850687  22423108  23949442  
GO:0004674protein serine/threonine kinase activity-TAS22899650  
GO:0004708MAP kinase kinase activity-IDA19302196  
GO:0005096GTPase activator activity-IDA17442267  
GO:0005515protein binding-IPI16321986  16352719  17400507  18367605  18445495  19176810  
19196961  19625296  19712061  20067578  20144646  20173330  
20642453  20671708  21048939  21159966  21307259  21370995  
21454543  21658387  21850687  21983832  22228096  22303461  
22363216  22612223  22639965  22899650  22952686  22998870  
23075850  23183827  23241358  23395371  23455607  23813973  
23937259  23949442  24113872  24165324  24275654  24282027  
24351927  24459295  24464040  24510904  24687852  24695735  
24725412  24754922  24794857  24904275  24947832  25009464  
25201882  25360523  25446991  25500533  25501810  25605758  
26824392  27013965  27273569  27314038  27357661  
GO:0005524ATP binding-IEA-  
GO:0005525GTP binding-IDA16980962  17260967  17442267  
GO:0005525GTP binding-TAS22899650  
GO:0008017microtubule binding-TAS24115276  
GO:0015631tubulin binding-IDA21159966  
GO:0016301kinase activity-IDA17114044  
GO:0016301kinase activity-IMP23916833  
GO:0017048Rho GTPase binding-IBA21873635  
GO:0017048Rho GTPase binding-IPI21048939  
GO:0017075syntaxin-1 binding-IPI21307259  
GO:0030159receptor signaling complex scaffold activity-IC22899650  
GO:0030276clathrin binding-IPI21307259  
GO:0034211GTP-dependent protein kinase activity-IDA17260967  
GO:0034211GTP-dependent protein kinase activity-IMP17200152  
GO:0036479peroxidase inhibitor activity-IDA21850687  
GO:0039706co-receptor binding-TAS24115276  
GO:0042802identical protein binding-IPI16321986  18230735  18397888  19712061  19733152  20515039  
21073465  22363216  22952686  23220480  23241358  24275654  
24591621  24904275  26824392  27013965  27357661  
GO:0042803protein homodimerization activity-IPI16321986  
GO:0044325ion channel binding-IPI21370995  22012985  
GO:0051018protein kinase A binding-IPI24464040  
GO:1904713beta-catenin destruction complex binding-NAS24115276  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-IDA17200152  
GO:0000186activation of MAPKK activity-IDA19302196  
GO:0000187activation of MAPK activity-IMP21857923  
GO:0001933negative regulation of protein phosphorylation-ISS-  
GO:0001934positive regulation of protein phosphorylation-IDA22012985  
GO:0001934positive regulation of protein phosphorylation-IMP20659558  
GO:0006468protein phosphorylation-IDA25500533  
GO:0006468protein phosphorylation-IMP23628791  
GO:0006897endocytosis-IGI24576675  
GO:0006897endocytosis-IMP24576675  
GO:0006914autophagy-IEA-  
GO:0006979response to oxidative stress-IMP19692353  
GO:0007005mitochondrion organization-IBA21873635  
GO:0007005mitochondrion organization-IMP22764206  
GO:0007030Golgi organization-IMP24510904  
GO:0007040lysosome organization-IMP25416817  
GO:0007283spermatogenesis-IEA-  
GO:0007528neuromuscular junction development-IMP21159966  
GO:0008340determination of adult lifespan-IMP19692353  
GO:0009267cellular response to starvation-IMP24211199  
GO:0010506regulation of autophagy-IMP24211199  
GO:0010508positive regulation of autophagy-IMP22012985  
GO:0010508positive regulation of autophagy-ISS-  
GO:0010738regulation of protein kinase A signaling-ISS-  
GO:0010955negative regulation of protein processing-IDA21370995  
GO:0010977negative regulation of neuron projection development-IEA-  
GO:0014041regulation of neuron maturation-IMP21168496  
GO:0016242negative regulation of macroautophagy-IMP19640926  
GO:0016310phosphorylation-IMP23916833  
GO:0018105peptidyl-serine phosphorylation-IDA19576176  
GO:0018107peptidyl-threonine phosphorylation-IDA21048939  
GO:0018107peptidyl-threonine phosphorylation-IMP23949442  
GO:0019722calcium-mediated signaling-IBA21873635  
GO:0019722calcium-mediated signaling-IMP25416817  
GO:0021756striatum development-IEA-  
GO:0021772olfactory bulb development-IMP21168496  
GO:0022028tangential migration from the subventricular zone to the olfactory bulb-IMP21168496  
GO:0031398positive regulation of protein ubiquitination-IDA16352719  20173330  
GO:0032091negative regulation of protein binding-IMP23949442  
GO:0032092positive regulation of protein binding-IDA21370995  
GO:0032436positive regulation of proteasomal ubiquitin-dependent protein catabolic process-ISS-  
GO:0033160positive regulation of protein import into nucleus, translocation-IEA-  
GO:0034260negative regulation of GTPase activity-IDA22423108  
GO:0034599cellular response to oxidative stress-IMP21362567  21857923  22764206  
GO:0034613cellular protein localization-ISS-  
GO:0035556intracellular signal transduction-ISS-  
GO:0035564regulation of kidney size-ISS-  
GO:0035640exploration behavior-IMP20659558  
GO:0035641locomotory exploration behavior-IEA-  
GO:0035751regulation of lysosomal lumen pH-IMP22012985  
GO:0040012regulation of locomotion-IMP19692353  
GO:0042391regulation of membrane potential-IMP21159966  
GO:0043068positive regulation of programmed cell death-IDA17200152  
GO:0043406positive regulation of MAP kinase activity-IC23628791  
GO:0043547positive regulation of GTPase activity-IEA-  
GO:0046039GTP metabolic process-IDA21048939  
GO:0046777protein autophosphorylation-IDA16269541  16321986  17200152  17442267  
GO:0046777protein autophosphorylation-IMP16980962  
GO:0048312intracellular distribution of mitochondria-IMP21159966  
GO:0048812neuron projection morphogenesis-IMP17114044  
GO:0051646mitochondrion localization-IMP22764206  
GO:0051770positive regulation of nitric-oxide synthase biosynthetic process-IEA-  
GO:0051900regulation of mitochondrial depolarization-IMP22736029  
GO:0051966regulation of synaptic transmission, glutamatergic-ISS-  
GO:0060070canonical Wnt signaling pathway-TAS24115276  
GO:0060079excitatory postsynaptic potential-ISS-  
GO:0060159regulation of dopamine receptor signaling pathway-ISS-  
GO:0060161positive regulation of dopamine receptor signaling pathway-IMP20659558  
GO:0060828regulation of canonical Wnt signaling pathway-TAS22988876  
GO:0061001regulation of dendritic spine morphogenesis-IBA21873635  
GO:0061001regulation of dendritic spine morphogenesis-IMP21168496  
GO:0061001regulation of dendritic spine morphogenesis-ISS-  
GO:0070585protein localization to mitochondrion-TAS24252804  
GO:0070997neuron death-IMP19692353  
GO:0071287cellular response to manganese ion-IMP23628791  
GO:0072593reactive oxygen species metabolic process-IMP24576675  
GO:0090140regulation of mitochondrial fission-TAS24252804  
GO:0090263positive regulation of canonical Wnt signaling pathway-IGI22899650  
GO:0090394negative regulation of excitatory postsynaptic potential-ISS-  
GO:0140058neuron projection arborization-IEA-  
GO:1900244positive regulation of synaptic vesicle endocytosis-IEA-  
GO:1901214regulation of neuron death-IMP24403142  
GO:1901215negative regulation of neuron death-IGI21857923  
GO:1901727positive regulation of histone deacetylase activity-IEA-  
GO:1902236negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway-IMP21857923  
GO:1902499positive regulation of protein autoubiquitination-IDA16352719  
GO:1902692regulation of neuroblast proliferation-IMP21168496  
GO:1902803regulation of synaptic vesicle transport-IBA21873635  
GO:1902803regulation of synaptic vesicle transport-ISS-  
GO:1902803regulation of synaptic vesicle transport-TAS21563316  
GO:1902823negative regulation of late endosome to lysosome transport-TAS23949442  
GO:1902902negative regulation of autophagosome assembly-IBA21873635  
GO:1902902negative regulation of autophagosome assembly-IMP23916833  
GO:1903125negative regulation of thioredoxin peroxidase activity by peptidyl-threonine phosphorylation-IDA21850687  
GO:1903206negative regulation of hydrogen peroxide-induced cell death-IMP24576675  
GO:1903215negative regulation of protein targeting to mitochondrion-IDA21370995  
GO:1903217negative regulation of protein processing involved in protein targeting to mitochondrion-IC21370995  
GO:1903351cellular response to dopamine-IMP23628791  
GO:1903980positive regulation of microglial cell activation-IEA-  
GO:1904469positive regulation of tumor necrosis factor secretion-IEA-  
GO:1904887Wnt signalosome assembly-IPI22899650  
GO:1904887Wnt signalosome assembly-TAS24115276  
GO:1905279regulation of retrograde transport, endosome to Golgi-IBA21873635  
GO:1905279regulation of retrograde transport, endosome to Golgi-IGI23395371  
GO:1905289regulation of CAMKK-AMPK signaling cascade-IMP22012985  
GO:2000172regulation of branching morphogenesis of a nerve-IMP21168496  
GO:2000300regulation of synaptic vesicle exocytosis-IMP23949442  
GO ID GO Term Qualifier Evidence PubMed
GO:0005615extracellular space-HDA22664934  
GO:0005622intracellular-IMP22012985  
GO:0005634nucleus-IDA-  
GO:0005737cytoplasm-IDA16321986  16352719  19625296  
GO:0005739mitochondrion-IDA21850687  
GO:0005741mitochondrial outer membrane-ISS-  
GO:0005743mitochondrial inner membrane-ISS-  
GO:0005759mitochondrial matrix-ISS-  
GO:0005764lysosome-IBA21873635  
GO:0005764lysosome-ISS-  
GO:0005768endosome-IBA21873635  
GO:0005768endosome-ISS-  
GO:0005783endoplasmic reticulum-IBA21873635  
GO:0005783endoplasmic reticulum-IDA19640926  
GO:0005783endoplasmic reticulum-ISS-  
GO:0005794Golgi apparatus-IBA21873635  
GO:0005794Golgi apparatus-IDA23395371  
GO:0005794Golgi apparatus-ISS-  
GO:0005798Golgi-associated vesicle-IDA24510904  
GO:0005802trans-Golgi network-IEA-  
GO:0005829cytosol-IBA21873635  
GO:0005829cytosol-IDA21850687  22736029  22899650  24403142  
GO:0005829cytosol-TAS-  
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membrane-IDA22899650  
GO:0005902microvillus-IDA19640926  
GO:0016234inclusion body-IMP24403142  
GO:0030054cell junction-IEA-  
GO:0030424axon-IDA17120249  
GO:0030424axon-ISS-  
GO:0030425dendrite-IDA17120249  
GO:0030425dendrite-ISS-  
GO:0030426growth cone-IDA19625296  
GO:0030672synaptic vesicle membrane-IEA-  
GO:0031410cytoplasmic vesicle-ISS-  
GO:0031966mitochondrial membrane-IBA21873635  
GO:0031966mitochondrial membrane-IDA22736029  
GO:0032473cytoplasmic side of mitochondrial outer membrane-IDA16269541  
GO:0032839dendrite cytoplasm-IDA21696411  
GO:0043005neuron projection-IBA21873635  
GO:0043005neuron projection-IDA19625296  21048939  
GO:0043025neuronal cell body-IDA21048939  21696411  
GO:0043195terminal bouton-TAS21563316  
GO:0043204perikaryon-IDA17120249  
GO:0043204perikaryon-ISS-  
GO:0043231intracellular membrane-bounded organelle-IDA-  
GO:0044753amphisome-IDA19640926  
GO:0044754autolysosome-IDA19640926  
GO:0045121membrane raft-IBA21873635  
GO:0070062extracellular exosome-HDA19056867  
GO:0097487multivesicular body, internal vesicle-IDA19640926  
GO:0098794postsynapse-IEA-  
GO:0099400caveola neck-IDA19640926  
GO:1990904ribonucleoprotein complex-IEA-  
GO:1990909Wnt signalosome-IDA22899650  
GO:1990909Wnt signalosome-NAS24115276  
KEGG ID KEGG Term
hsa05012Parkinson's disease
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionTAS
R-HSA-8848021Signaling by PTK6TAS
R-HSA-8857538PTK6 promotes HIF1A stabilizationTAS
R-HSA-9006927Signaling by Non-Receptor Tyrosine KinasesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25493281Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker? (2014 Sep)Saunders-Pullman RAnn Clin Transl Neurol
21494699Cancer and Parkinson's disease: the odd couple. (2011 Mar)Gao XDrugs Today (Barc)
23055790Environmental-genetic interactions in the pathogenesis of Parkinson's disease. (2012 Sep)Tsuboi YExp Neurobiol
28472425Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder. (2017 Aug 1)Barber TRSleep
28289797[Epidemiology and causes of Parkinson's disease]. (2017 Apr)Lill CMNervenarzt
22763023An exploratory analysis on gene-environment interactions for Parkinson disease. (2012 Oct)Gao JNeurobiol Aging
25401981Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. (2015 Jan)Agalliu IJAMA Neurol
20673920LRRK2 Gly2385Arg polymorphism, cigarette smoking, and risk of sporadic Parkinson's disease: a case-control study in Japan. (2010 Oct 15)Miyake YJ Neurol Sci
27411784Inflexible ethanol intake: A putative link with the Lrrk2 pathway. (2016 Oct 15)da Silva E Silva DABehav Brain Res